Curaleaf (OTCMKTS:CURLF – Get Free Report) and Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.
Earnings & Valuation
This table compares Curaleaf and Vivos Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Curaleaf | $1.27 billion | 1.76 | -$231.07 million | ($0.13) | -73.62 |
| Vivos Therapeutics | $20.90 million | 0.12 | -$21.17 million | ($1.90) | -0.09 |
Profitability
This table compares Curaleaf and Vivos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Curaleaf | -2.62% | -0.88% | -0.26% |
| Vivos Therapeutics | -122.00% | -2,325.64% | -102.01% |
Analyst Ratings
This is a breakdown of recent ratings for Curaleaf and Vivos Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Curaleaf | 0 | 0 | 2 | 3 | 3.60 |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 1,455.56%. Given Vivos Therapeutics’ higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than Curaleaf.
Volatility & Risk
Curaleaf has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.04, indicating that its share price is 504% more volatile than the S&P 500.
Institutional and Insider Ownership
0.0% of Curaleaf shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Curaleaf beats Vivos Therapeutics on 8 of the 14 factors compared between the two stocks.
About Curaleaf
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
